新修订《药品管理法实施条例》发布，首次引入儿童用药品及罕见病药品市场独占期

Core Viewpoint - The revised Implementation Regulations of the Drug Administration Law of the People's Republic of China introduces support for the development and innovation of pediatric and rare disease medications, establishing a market exclusivity period for these categories for the first time [1] Group 1: Pediatric Medications - The regulations provide a market exclusivity period of up to 2 years for new pediatric drug varieties, new dosage forms or specifications, and drugs that add pediatric indications, provided they meet certain conditions [1] - The specific conditions and methods for granting market exclusivity will be determined by the State Council's drug regulatory authority [1] Group 2: Rare Disease Medications - For rare disease treatment medications, a market exclusivity period of up to 7 years is granted if the drug market authorization holder commits to ensuring the supply of the medication [1] - If the drug market authorization holder fails to fulfill the commitment to ensure supply, the market exclusivity period will be terminated [1]